



25 November 2015

The Company Announcements Platform
ASX Limited
By E-lodgement

Additional Placement Raises \$1.0 million

Melbourne, Australia, 24 November 2015: Cancer drug development company Prescient Therapeutics Limited (ASX: PTX) ('Prescient', 'PTX' or 'the Company') advises that following the oversubscribed Share Purchase Plan ('SPP'), the Company has subsequently raised approximately \$1.0 million. The Company is completing an additional top up placement of approximately 19.3 million fully paid ordinary shares at \$0.054 (5.4 cents) per share, which is the same price as the SPP issue price. Together with the recently completed SPP, PTX has raised approximately \$2.0 million, exceeding the Company's expectations.

PTX expects these funds to provide for efforts to achieve multiple milestones across its clinical programs over the next 12 to 18 months. More specifically, this capital will enable the Company to:

- Initiate and complete a Phase 1b Acute Myeloid Leukemia trial at the Moffitt Cancer Center in Florida;
- Commence recruitment for Phase 2 breast cancer trial at the Montefiore Medical Center in New York (part of the Albert Einstein College of Medicine); and
- Continue patient recruitment to a key Phase 1b ovarian cancer trial already underway at the Moffitt Cancer Center.

Chairman Steven Engle said the Company is on the brink of realising some of the potential value form its key assets and in particular, from drug candidate PTX-200.

"Shareholders should note these programs are buoyed by existing strong relationships with highly respected US cancer centers where our trials are being conducted. In addition, our programs are supported by significant grants from the US Department of Defense and the US National Cancer Institute," he said.

"In short, we are running these studies frugally with some of the best cancer center partners and experts in the world. To be able to conduct three separate clinical trials and generate data with such a modest amount of capital is exceptional."

The Board wishes to thank all shareholders for their continued support and level of interest shown through throughout the recent SPP and this additional placement.

This share issue will fall under the approval provided by the Company's shareholders at the Annual General Meeting held on 4 November 2015 and so will not require additional approval.

Further Inquiries:

Paul Hopper

Executive Director
+61 406 671 515

Rudi Michaelson

Monsoon Communications
+61 (0) 3 9620 3333

About Prescient Therapeutics Limited (PTX)

PTX is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. This highly promising compound is now the focus of two current clinical trials. The first is a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York. A Phase 1b/2 trial of the compound in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at Florida's H. Lee Moffitt Cancer Center. These trials are funded in part by grants from the U.S. National Cancer Institute. In addition, PTX is planning a Phase 1b/2 trial evaluating PTX-200 as a new therapy for acute myeloid leukemia.

PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors.

PTX has licensed access to its Co-X-Gene™ platform technology to French biotechnology company Transgene for use in two immunotherapeutic products.